4.7 Article

Progress against non-Hodgkin's lymphoma in children and young adolescents in the Netherlands since 1990: Stable incidence, improved survival and lower mortality

期刊

EUROPEAN JOURNAL OF CANCER
卷 163, 期 -, 页码 140-151

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2021.12.010

关键词

Cancer epidemiology; Incidence; Mortality; Non-Hodgkin's lymphoma; Paediatric oncology; Survival; Trends

类别

资金

  1. Stichting Kinderen Kankervrij (KiKa) [207]
  2. Steunfonds Vrienden Integrale Oncologische Zorg (VIOZ)

向作者/读者索取更多资源

This population-based epidemiological study in the Netherlands shows significant progress against childhood and young adolescent NHL since 1990. The incidence of NHL has decreased among children aged 5-9, while survival rates have improved and mortality rates have steadily decreased over time.
Background: With epidemiologic analyses of population-based trends in incidence and outcomes, we ascertained progress against non-Hodgkin's lymphoma (NHL) in children and young adolescents in the Netherlands since 1990.Methods: Tumour characteristics were extracted from the Netherlands Cancer Registry for patients aged <18 years at diagnosis, between 1990 and 2015. Mortality data for 1980-2016 were derived from Statistics Netherlands. NHL subtypes comprised lymphoblastic lymphoma (LBL), Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and anaplastic large cell lymphoma (ALCL). Time trends in incidence and mortality rates and 5-year overall survival (OS) rates were evaluated by average annual percentage change (AAPC) analyses and parametric survival models, respectively.Results: Overall incidence of NHL remained stable at 11 per million person-years (AAPC-0.2 %, p Z 0.68), with a marked decrease among children of 5-9 years (AAPC-2. 6%, p < 0.01), especially among those with BL. Treatment regimens comprised less radiotherapy over time, especially for LBL and BL. Since 2004, most 15-17-year-old patients with NHL have been treated at a paediatric oncology centre. Five-year OS improved from 71% in 1990-94 to 87% in 2010-15 (p < 0.01), the most gain has been achieved in patients with DLBCL and ALCL from 60% and 73%, respectively, to both 90%. Population-based mortal-ity from NHL decreased significantly towards 1.4 per million person-years (AAPC-4.2%, p < 0.01). Conclusions: This population-based epidemiological study exhibited significant progress against childhood and young adolescent NHL in the Netherlands since 1990, before the advent of a national paediatric oncologic centre in 2018: incidence decreased among children of 5-9 years, survival improved, and mortality steadily decreased over time. 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据